These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33870157)

  • 1. Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters.
    Lin SR; Yang TY; Peng CY; Lin YY; Dai CY; Wang HY; Su TH; Tseng TC; Liu IJ; Cheng HR; Shen YC; Wu FY; Liu CJ; Chen DS; Chen PJ; Yang HC; Kao JH
    JHEP Rep; 2021 Jun; 3(3):100254. PubMed ID: 33870157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion.
    Cheng Y; Guindon S; Rodrigo A; Wee LY; Inoue M; Thompson AJ; Locarnini S; Lim SG
    Gut; 2013 Sep; 62(9):1347-55. PubMed ID: 23242209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients.
    Yang J; Yang G; He H; Ning L; Liu Z; Fu Q; Chen H; Deng H; Wang Z; Luo K
    Antivir Ther; 2018; 23(7):567-574. PubMed ID: 30095435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy.
    Cheng Y; Guindon S; Rodrigo A; Lim SG
    J Hepatol; 2013 Feb; 58(2):217-24. PubMed ID: 23023011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion.
    Wu S; Imazeki F; Kurbanov F; Fukai K; Arai M; Kanda T; Yonemitsu Y; Tanaka Y; Mizokami M; Yokosuka O
    J Hepatol; 2011 Jan; 54(1):19-25. PubMed ID: 20932594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
    Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
    Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of BCP/PreC/C region quasispecies in treatment-naive patients with different phases of HBV infection using next-generation sequencing.
    Zhu C; Tang M; Fu Y; Xun Z; Lin C; Wu S; Chen T; Zeng Y; Yang B; Ou Q; Liu C
    Int J Med Microbiol; 2024 Jun; 315():151619. PubMed ID: 38564936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion.
    Chen CH; Lu SN; Lee CM; Hung CH; Wang JH; Hu TH
    Hepatol Int; 2014 Jul; 8(3):365-74. PubMed ID: 26202639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients.
    Yu XQ; Wang MJ; Yu DM; Chen PZ; Zhu MY; Huang W; Han Y; Gong QM; Zhang XX
    J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32554476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
    Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.
    Kuo LF; Lee CM; Hung CH; Wang JH; Hu TH; Lu SN; Changchien CS; Chen CH
    Dig Dis Sci; 2014 Oct; 59(10):2580-7. PubMed ID: 24846794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral quasi-species evolution during hepatitis Be antigen seroconversion.
    Lim SG; Cheng Y; Guindon S; Seet BL; Lee LY; Hu P; Wasser S; Peter FJ; Tan T; Goode M; Rodrigo AG
    Gastroenterology; 2007 Sep; 133(3):951-8. PubMed ID: 17854598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation.
    Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.
    Chuaypen N; Payungporn S; Poovorawan K; Chotiyaputta W; Piratvisuth T; Tangkijvanich P
    Virus Genes; 2019 Oct; 55(5):610-618. PubMed ID: 31359359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
    Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
    Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.